Flinn, Ian W.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 6,030

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 2,286

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 2,270

KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma

Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,862

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,607

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,516

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 769

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 446

AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 434

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., et al. (2018) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 373

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 351

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., Davis, R. E., et al. (2021) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 199

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., et al. (2023) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchPhagocytosis and Immune Regulation

Cited by 188

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Mato, A. R., Wierda, W. G., Ai, W. Z., Flinn, I. W., Tees, M., Patel, M. R., Patel, K., O'Brien, S., Bond, D. A., Roeker, L. E., et al. (2022) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 74

Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning—Monte Carlo Simulation Studies

He, B., Wahl, R. L., Du, Y., Sgouros, G., Jacene, H., Flinn, I., & Frey, E. C. (2008) · IEEE Transactions on Medical Imaging

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 53

Safety and Preliminary Efficacy Results of a Phase I First‐in‐Human Study of the Novel Notch‐1 Targeting Antibody Brontictuzumab (OMP‐52M51) Administered Intravenously to Patients with Hematologic Malignancies

Casulo, C., Ruan, J., Dang, N. H., Gore, L., Diefenbach, C., Beaven, A. W., Castro, J. E., Porcu, P., Faoro, L., Dupont, J., et al. (2016) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 35

Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the in-111 (111in)/yttrium 90 (90y) ibritumomab tiuxetan (Zevalin®) theranostic pair in patients with lymphoma at myeloablative dose levels

Wahl, R. L., Frey, E. C., Jacene, H. A., Kahl, B. S., Piantadosi, S., Bianco, J. A., Hammes, R. J., Jung, M., Kasecamp, W., He, B., et al. (2021) · Cancers

Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and Treatment

Cited by 14

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Li, C.-C., Bender, B., Yin, S., Li, Z., Zhang, C., Hernandez, G., Kwan, A., Sun, L., Adamkewicz, J. I., Wang, H., et al. (2019) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 14